Role of T Cell Subsets in Lethal Graft-versus-host Disease (GVHD) Directed to Class I Versus Class II H-2 Differences. I. L3T4+ Cells Can Either Augment or Retard GVHD Elicited by Lyt-2+ Cells in Class I Different Hosts
Overview
General Medicine
Authors
Affiliations
Detailed information was sought on the capacity of purified Lyt-2+ cells to mediate lethal graft-versus-host disease (GVHD) directed to class I H-2 differences. When B6 Lyt-2+ cells were transferred to irradiated class I-different (B6 x bm 1)F1 mice, three different patterns of lethal GVHD were observed. First, rapid death from hematopoietic failure occurred when Lyt-2+ cells were transferred together with host-type marrow cells; this form of GVHD probably reflected direct destruction of stem cells by Lyt-2+ cytotoxic cells. Second, a pattern of late-onset, chronic GVHD resulting in death only after 4-6 wk occurred when Lyt-2+ cells were supplemented with donor marrow. This syndrome developed in the apparent absence of L3T4+ cells and was observed with either high or low doses of Lyt-2+ cells and with either light or heavy irradiation of the host. Third, an acute form of GVHD resulted when Lyt-2+ cells plus donor marrow cells were supplemented with exogenous help, i.e., by adding small doses of donor L3T4+ cells or injecting the hosts with rIL-2. Although L3T4+ cells potentiated GVHD when injected in small doses, supplementing Lyt-2+ cells with large doses of L3T4+ cells paradoxically led to marked protection; symptoms of GVHD were mild and no deaths occurred.
Vo T, Kumar R, Lamichhane R, Choudhary I, Kc R, Mao Y STAR Protoc. 2024; 6(1):103504.
PMID: 39700013 PMC: 11728988. DOI: 10.1016/j.xpro.2024.103504.
Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A, Sligar C, Cuthbertson P, Watson D, Sluyter R Biosci Rep. 2022; 42(9).
PMID: 35993192 PMC: 9446388. DOI: 10.1042/BSR20211986.
Cuthbertson P, Geraghty N, Adhikary S, Bird K, Fuller S, Watson D Int J Mol Sci. 2021; 22(15).
PMID: 34361109 PMC: 8348324. DOI: 10.3390/ijms22158343.
Gaignage M, Marillier R, Uyttenhove C, Dauguet N, Saxena A, Ryffel B Immun Inflamm Dis. 2017; 5(2):200-213.
PMID: 28474504 PMC: 5418140. DOI: 10.1002/iid3.157.
Pathophysiology of GvHD and Other HSCT-Related Major Complications.
Ghimire S, Weber D, Mavin E, Wang X, Dickinson A, Holler E Front Immunol. 2017; 8:79.
PMID: 28373870 PMC: 5357769. DOI: 10.3389/fimmu.2017.00079.